SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

The community is actively discussing the potential acquisition of Churchill Capital Corp XI following the merger announcement with Agility Robotics, with many investors debating the long-term viability of the robotics sector and comparing the situation to previous SPAC experiences. Bullish sentiment is driven by the company's backing from major tech players, while others remain skeptical, warning of potential volatility and cautioning against post-merger price fluctuations.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending as investors debate whether the recent volatility represents a healthy consolidation phase or a deeper structural correction within the AI hardware supply chain. The community is focused on the critical role of Indium Phosphide (InP) substrates as a production bottleneck for high-speed AI optical networking, with ongoing discussions centered on whether recent price fluctuations offer an accumulation window or signal potential downside risks.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibre is trending as investors debate whether the recent double-digit sell-off, sparked by margin compression from heavy reinvestments in logistics and fintech, is a fundamental breakdown or a generational buying opportunity. Community sentiment remains deeply divided, with bulls pointing to the company's 49% revenue growth and dominant Latin American ecosystem as evidence of long-term compounding, while bears express frustration over price action and the ongoing impact of competitive spending.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased community activity and speculation as the impending launch of the Goliath mainnet approaches. Investors are debating its long-term potential for institutional financial infrastructure, with polarized views between those accumulating for the catalyst and skeptics wary of previous market volatility and lack of transparent partnerships.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investors rotate into defensive healthcare stocks amid market-wide positioning stress and shifting risk appetite, while simultaneously drawing attention for its aggressive pipeline M&A and clinical progress with Keytruda combinations. The community is actively debating the company's ability to navigate the upcoming patent cliff while monitoring potential buyout targets and competitive threats in the oncology space.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is seeing significant investor attention following a broader sector rotation into defensive, high-cash-flow healthcare stocks as capital shifts away from higher-beta technology shares. Community discussion is heavily focused on the company's recent strategic M&A activity to strengthen its drug development pipeline and its ability to maintain strong performance despite broader market volatility.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. The company operates through the OSS and OSS Europe segments. One Stop Systems was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is seeing significant attention from investors following strong Q1 earnings, a robust book-to-bill ratio, and ongoing momentum as a specialized provider of rugged AI edge computing for defense and autonomous systems. The community is actively discussing the stock's potential for institutional inflows through Russell 3000 inclusion, while monitoring for catalysts related to long-term government defense contracts and the broader expansion of edge AI infrastructure.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending as market sentiment shifts toward its strong fundamental turnaround, characterized by significant revenue growth, improved medical loss ratios, and recent institutional accumulation. Investors are closely watching its breakout momentum as the stock reclaims multi-year structural levels while bullish sentiment increases following management's reaffirmed guidance and successful Q1 performance.

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

Symbotic is garnering significant community attention due to its massive $22.7 billion contracted backlog, which provides high revenue visibility as it scales its AI-driven warehouse automation systems for major retail and healthcare partners. Investors are actively debating the company's valuation and execution risks, with many viewing the recent pullback as a potential accumulation zone for a long-term play on physical AI and industrial robotics.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors rotate into defensive healthcare stocks, further fueled by robust clinical data for its next-generation obesity and metabolic treatments. Market sentiment is also reacting to the company's aggressive expansion strategy, marked by a series of strategic acquisitions and high-profile partnerships aimed at diversifying its pipeline beyond current blockbusters.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Veradermics (MANE) points to a 27.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Veradermics to Present at Upcoming June Investor Conferences

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in June...

Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 302 Study of VDPHL01 at the 2026 World Congress for Hair Research

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that topline results from Phase 2/3 302 Study of VDPHL01 will be presented at the 2026 World Congress...

This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO

Key PointsSiren initiated a new position by acquiring 1,505,374 shares of Veradermics; the estimated transaction value is $75.94 million based on quarterly average pricing...

Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced...

Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported...

Citi Remains Bullish on Veradermics, Incorporated (MANE)

Citi Remains Bullish on Veradermics, Incorporated (MANE...

MANE Study 302: Veradermics Posts Positive Top-Line Phase II/III Results for Oral Minoxidil Pill

Veradermics reported positive top line results from Part A of its Phase II/III 302 trial evaluating VDPHL01, an oral extended-release minoxidil tablet, in men with mild to moderate pattern hair loss...

Veradermics Announces Pricing of Upsized Public Offering and Private Placement

Veradermics, Incorporated (Veradermics) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today...

Veradermics Announces Launch of Public Offering

Veradermics, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company was founded in 2019 and is headquartered in New Haven, CT.

Veradermics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$126.89
Prev Close	$119.37
Open	$117.64
Dividend Yield	N/A
50-Day Moving Average	$97.15
Beta	-0.45
Avg. Volume	568,136.97
PE Ratio	N/A

52-Week High	$121.45
52-Week Low	$17.00
Market Capitalization	$5.3B
EPS (Annual)	-$2.23
Price to Book	11.37
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

MANEVeradermics Inc

Latest MANE News